BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 26114729)

  • 1. Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's disease: interim results from the long-term, large-scale J-GOLD study in Japan.
    Arai H; Sumitomo K; Sakata Y; Daidoji K; Takase T; Toyoda T
    Psychogeriatrics; 2016 Mar; 16(2):107-15. PubMed ID: 26114729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's disease: Japan-Great Outcome of Long-term trial with Donepezil (J-GOLD).
    Arai H; Hashimoto N; Sumitomo K; Takase T; Ishii M
    Psychogeriatrics; 2018 Sep; 18(5):402-411. PubMed ID: 29993162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study.
    Yatabe Y; Hashimoto M; Kaneda K; Honda K; Ogawa Y; Yuuki S; Ikeda M
    Psychogeriatrics; 2013 Jun; 13(2):88-93. PubMed ID: 23909965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
    Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
    Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.
    Nozawa M; Ichimiya Y; Nozawa E; Utumi Y; Sugiyama H; Murayama N; Iseki E; Arai H
    Psychogeriatrics; 2009 Jun; 9(2):50-5. PubMed ID: 19604325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy.
    Winblad B; Wimo A; Engedal K; Soininen H; Verhey F; Waldemar G; Wetterholm AL; Haglund A; Zhang R; Schindler R
    Dement Geriatr Cogn Disord; 2006; 21(5-6):353-63. PubMed ID: 16508298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease.
    Oka M; Nakaaki S; Negi A; Miyata J; Nakagawa A; Hirono N; Mimura M
    Psychogeriatrics; 2016 Mar; 16(2):121-34. PubMed ID: 26114924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of donepezil hydrochloride on the care burden of family caregivers of patients with Alzheimer's disease.
    Hashimoto M; Yatabe Y; Kaneda K; Honda K; Ikeda M
    Psychogeriatrics; 2009 Dec; 9(4):196-203. PubMed ID: 20377821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
    Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
    J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
    López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
    Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease.
    Tei E; Yamamoto H; Watanabe T; Miyazaki A; Nakadate T; Kato N; Mimura M
    Growth Horm IGF Res; 2008 Feb; 18(1):47-54. PubMed ID: 17714966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study.
    Rogers SL; Friedhoff LT
    Eur Neuropsychopharmacol; 1998 Feb; 8(1):67-75. PubMed ID: 9452942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
    López-Pousa S; Olmo JG; Franch JV; Estrada AT; Cors OS; Nierga IP; Gelada-Batlle E
    Age Ageing; 2006 Jul; 35(4):365-71. PubMed ID: 16788079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
    Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
    Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?
    Hashimoto M; Kazui H; Matsumoto K; Nakano Y; Yasuda M; Mori E
    Am J Psychiatry; 2005 Apr; 162(4):676-82. PubMed ID: 15800138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of donepezil dose escalation in Parkinson's patients with dementia receiving long-term donepezil treatment: an exploratory study.
    Ishikawa K; Motoi Y; Mizuno Y; Kubo S; Hattori N
    Psychogeriatrics; 2014 Jun; 14(2):93-100. PubMed ID: 24661498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
    Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
    J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.
    Sabbagh M; Cummings J; Christensen D; Doody R; Farlow M; Liu L; Mackell J; Fain R
    BMC Geriatr; 2013 Jun; 13():56. PubMed ID: 23742728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
    Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T
    Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.